HDAC9 and systemic sclerosis: These studies and other functional studies revealed hundreds of potential candidates of epigenetic-modifying drugs in SSc, including DNMT inhibitors (5-azaC and 5-aza), HDAC inhibitors (TSA and MC1568), a HAT inhibitor (SGC-CBP30), SIRT activators (resveratrol, SRT1720, and hexafluoro), EZH2 inhibitors (DZNep and GSK126), a JMJD3 inhibitor (GSKJ4), BET bromodomain inhibitor (JQ1), and miRNAs [115].